Add to ORKGAstraZeneca and shareholder. The remaining authors declare no competing financial interests. Financial support: None. N. Raje is a recipient of the Leukemia & Lymphoma Society clinical scholar Award Address correspondence to
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Subtotal lymph node irradiation Disclosures: The author indicated no financial relationships. Recent...
aCo-first authors The authors disclose no potential conflicts of interest Financial suppor
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinase...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
merase II alpha, microtubule-associat-ed protein-tau, anthracycline, taxane. Acknowledgments:We than...
Running title: miRNA-26b regulates cancer proliferation Conflict of Interest: The authors have no co...
Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, includ...
RLF reports receiving commercial research grants from Bristol-Myers Squibb, Merck, and Astra Zeneca....
Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth Running title: ...
Resistance to the mechanistic target of rapamycin (mTOR) inhibitors, which are a standard treatment ...
Inhibition of c-Myc down-regulation by sustained ERK activation prevents the antimetabolite methotre...
1 Phase I clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute...
Table of contents for this issue and main article; The phosphatidylinositol 3-kinase (PI3K)/Akt/mamm...
Key words: sentinel lymph node, breast cancer, macroscopic diagnosis, intraoperative diagnosis. Comp...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Subtotal lymph node irradiation Disclosures: The author indicated no financial relationships. Recent...
aCo-first authors The authors disclose no potential conflicts of interest Financial suppor
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinase...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
merase II alpha, microtubule-associat-ed protein-tau, anthracycline, taxane. Acknowledgments:We than...
Running title: miRNA-26b regulates cancer proliferation Conflict of Interest: The authors have no co...
Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, includ...
RLF reports receiving commercial research grants from Bristol-Myers Squibb, Merck, and Astra Zeneca....
Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth Running title: ...
Resistance to the mechanistic target of rapamycin (mTOR) inhibitors, which are a standard treatment ...
Inhibition of c-Myc down-regulation by sustained ERK activation prevents the antimetabolite methotre...
1 Phase I clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute...
Table of contents for this issue and main article; The phosphatidylinositol 3-kinase (PI3K)/Akt/mamm...
Key words: sentinel lymph node, breast cancer, macroscopic diagnosis, intraoperative diagnosis. Comp...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Subtotal lymph node irradiation Disclosures: The author indicated no financial relationships. Recent...
aCo-first authors The authors disclose no potential conflicts of interest Financial suppor